BioTech IP Review

Published in PNAS (September 5, 2025) — a major advance in gene-editing delivery technology by Zhenyu Han, Chi Huang, Taokun Luo, Chad A. Mirkin, and colleagues.

What the study covers

This PNAS paper reports the development of CRISPR lipid nanoparticle spherical nucleic acids (LNP-SNAs) — a novel delivery platform that dramatically improves the efficiency and safety of CRISPR-Cas gene editing in cells.

• The researchers engineered spherical nucleic acid-coated lipid nanoparticles that carry the full set of CRISPR components — including Cas9 enzyme, guide RNA, and donor DNA repair templates — inside a dense shell of DNA.
• These LNP-SNAs enter cells significantly more efficiently (2–3× higher uptake) than conventional lipid nanoparticles, without increasing toxicity.
• Across multiple human and animal cell types, the LNP-SNA system boosted gene-editing efficiency two- to three-fold compared with standard lipid delivery platforms.
• When co-delivered with DNA repair templates, homology-directed repair efficiency also improved notably, indicating stronger precise editing outcomes.

Why it’s important

Efficient delivery of CRISPR-Cas systems into target cells remains one of the greatest challenges in translating gene editing into safe, effective therapies. Traditional viral vectors and existing lipid nanoparticles can be inefficient, toxic, or immunogenic — limiting clinical potential.

This study’s LNP-SNA platform tackles those barriers head-on:

• Higher cellular uptake — improving editing outcomes while reducing the amount of material needed.
• Reduced cytotoxicity — better biocompatibility important for therapeutic applications.
• Enhanced precision editing — increasing rates of homology-directed repair supports therapeutic gene correction strategies.

By combining advanced nanotechnology with genome editing, this work lays a stronger foundation for next-generation gene therapies that are safer, more effective, and easier to deliver across tissues — a critical milestone in biotech landscape.